Health
The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®
PARIS, March 20, 2026--Regulatory News: The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the first patients have been treated in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®.1 The REVISE do
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/44d2c618ff1f88b868698b5745d7b7a6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/x5UZjnWdgWKkcLxtnNn2.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwOA--/https://media.zenfs.com/en/business-wire.com/44d2c618ff1f88b868698b5745d7b7a6","width":480,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The first group of patients in the GS010 AAC program were treated at the 15-20 National Hospital in Paris on March 19.","length":118,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The REVISE dose-ranging study is proceeding according to the planned timeline.","length":78,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":196,"olType":false},{"type":"text","content":"PARIS, March 20, 2026--(BUSINESS WIRE)--Regulatory News:","length":56,"tagName":"p"},{"type":"text","content":"The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the first patients have been treated in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®.1 The REVISE dose-ranging study, which is being conducted in parallel, has enrolled the next three patients.","length":553,"tagName":"p"},{"type":"text","content":"First patients treated in the GS010 AAC program","length":47,"tagName":"p"},{"type":"text","content":"Following the recent authorization of the first named patient requests, an initial group of patients in the GS010 AAC program were treated at the 15-20 National Hospital in Paris on March 19. More treatments are scheduled in the coming weeks.","length":242,"tagName":"p"},{"type":"text","content":"GS010 is a candidate gene therapy in clinical development for the treatment of Leber Hereditary Optic Neuropathy (LHON) caused by a mutation in the ND4 mitochondrial gene. LHON patients suffer precipitous, usually irreversible vision loss caused by the rapid degeneration of their retinal ganglion cells (RGCs)...